Entity

Time filter

Source Type


Ferrer A.,Laboratori Of Citologia Hematologica | Lopez-Guillermo A.,Hospital Clinic
European journal of Clinical and Medical Oncology | Year: 2010

Mantle cell lymphoma (MCL) is a lymphoid neoplasm derived from mature B cells that represents 5-10% of non-Hodgkin lymphomas. MCL usually has an adverse clinical course characterized by a poor response to chemotherapy and a median overall survival of 3-5 years. Extranodal involvement, including central nervous system (CNS) infiltration, is a well-known feature of this disease. The incidence of CNS involvement in patients with MCL has been reported to range from 4% to 26%, with blastoid histology being one of the most relevant predicting factors for this complication. In most cases, CNS infiltration is a late event in the course of the disease. Treatment of this complication usually includes intrathecal chemotherapy in combination or not with systemic chemotherapy, frequently with high-dose methotrexate (MTX). However, once CNS infiltration is diagnosed, the prognosis is dismal and most patients die in less than 1 year. The relatively high risk of CNS involvement leads to the question of whether or not treatment strategies should take into consideration such a complication in all patients with MCL or only in a subset of them. However, the role of intravenous high-dose MTX as CNS prophylaxis in MCL is doubtful and, on the other hand, CNS infiltration is almost invariably part of disseminated disease, and the cause of death is systemic progression in virtually all patients. Therefore, CNS prophylaxis should be investigated as part of better therapies for this type of lymphoma. Source


Baro C.,Laboratori Of Citogenetica Molecular | Baro C.,Autonomous University of Barcelona | Espinet B.,Laboratori Of Citogenetica Molecular | Salido M.,Laboratori Of Citogenetica Molecular | And 10 more authors.
Leukemia Research | Year: 2011

Follicular lymphoma (FL) is one of the most common non-Hodgkin lymphomas (NHL). Translocation t(14;18)(q32;q21) involving IGH and BCL2 genes represents its genetic hallmark. We present six cases of a series of 75 well diagnosed FL patients in which variant fluorescence in situ hybridization (FISH) patterns for this rearrangement were found. Moreover, G-banding cytogenetics and polymerase chain reaction (PCR) methods were unable to detect t(14;18)(q32;q21). According to our results, FISH is the best technique to define variant rearrangements of IGH/. BCL2 genes and is important to detect it in cases with non-conclusive FL characteristics to avoid misdiagnosis with other NHL. © 2010 Elsevier Ltd. Source


Puiggros A.,Programa de Recerca en Cancer | Puigdecanet E.,Servei dAnalisi de Microarrays | Salido M.,Programa de Recerca en Cancer | Salido M.,Laboratori Of Citogenetica Molecular | And 21 more authors.
Leukemia and Lymphoma | Year: 2013

Chronic lymphocytic leukemia (CLL) is characterized by a highly variable clinical course. Del(11q) and del(17p), routinely studied by conventional G-banding cytogenetics (CGC) and fluorescence in situ hybridization (FISH), have been related to progression and shorter overall survival. Recently, array-based karyotyping has gained acceptance as a high-resolution new tool for detecting genomic imbalances. The aim of the present study was to compare genomic arrays with CGC and FISH to ascertain whether the current techniques could be substituted in routine procedures. We analyzed 70 patients with CLL using the Cytogenetics Whole-Genome 2.7M Array and CytoScan HD Array (Affymetrix), CGC and FISH with the classical CLL panel. Whereas 31.4% and 68.6% of patients presented abnormalities when studied by CGC and FISH, respectively, these rates increased when arrays were also analyzed (78.6% and 80%). Although abnormality detection is higher when arrays are applied, one case with del(11q) and three with del(17p) were missed by genomic arrays due to their limited sensitivity. We consider that the complete substitution of CGC and FISH by genomic arrays in routine laboratories could negatively affect the management of some patients harboring 11q or 17p deletions. In conclusion, genomic arrays are valid to detect known and novel genomic imbalances in CLL, but should be maintained as a complementary tool to the current techniques. © 2013 Informa UK, Ltd. Source

Discover hidden collaborations